- Ionis Innovation Day: Discovering, Developing and Delivering
Transformational Medicines
- Presentations by key members of Ionis leadership and notable
KOLs
CARLSBAD, Calif., Sept. 12,
2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc.
(Nasdaq: IONS) announced today that it will host an investor and
analyst day on Wednesday, October 4.
The event will take place at the Westin New York Grand Central from
8:00 a.m. to 3:00 p.m. Eastern Time
and will also be webcast. The agenda will include presentations by
members of the Ionis management team and the following notable key
opinion leaders:
- Henry N. Ginsberg, M.D., Irving professor of medicine,
Vagelo College of Physicians and Surgeons,
Columbia University; and
- Raffi Tachdjian, M.D., MPH,
FAAAAI, FACAAI, associate clinical professor of medicine and
pediatrics, UCLA School of Medicine, and chief, division of allergy
& immunology, Providence St. John Medical Center.
Please click here to register for the event. Webcast
participants may submit questions via email at
IonisInnovationDay@ionisph.com. Questions must be received by
October 2 to be addressed during the
live event. A webcast replay will be available within 48 hours
after the event
at https://ir.ionispharma.com/events-and-presentations/upcoming-events.
About Ionis Pharmaceuticals, Inc.
For more than 30 years, Ionis has been a leader in RNA-targeted
therapy, pioneering new markets and changing standards of care.
Ionis currently has four marketed medicines and a promising
late-stage pipeline highlighted by cardiovascular and neurological
franchises. Our scientific innovation began and continues with the
knowledge that sick people depend on us, which fuels our vision to
become the leader in genetic medicine, utilizing a multi-platform
approach to discover, develop and deliver life-transforming
therapies.
To learn more about Ionis visit www.ionispharma.com and follow
us on Twitter @ionispharma.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ionis-to-host-investor-and-analyst-day-event-301923994.html
SOURCE Ionis Pharmaceuticals, Inc.